Skip to content
PeptideAgent

Compounding pharmacies in Idaho

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

The Idaho State Board of Pharmacy (Division of Occupational and Professional Licenses) regulates compounding pharmacies in Idaho. Compounded GLP-1 limited. How to check a pharmacy's license, plus verified listings.

Idaho at a glance

503A framework
Follows the federal 503A framework
Telehealth prescribing
Regulatory: Telehealth allowed
Asynchronous prescribing
Regulatory: Async allowed
Compounded GLP-1 access
Regulatory: Compounded GLP-1 limited

Verified compounding pharmacies serving Idaho

No verified compounding pharmacies serving Idaho are listed yet. A provider appears here only after it passes the verification checklist, and those checks are still under way.

Looking for care now? Start with what the law allows where you live, then how a legitimate prescription works.

Run a pharmacy, clinic, or telehealth service? Apply for a listing.

Who regulates compounding pharmacies in Idaho

The Idaho State Board of Pharmacy, administered by the Division of Occupational and Professional Licenses, regulates compounding under the Idaho Pharmacy Act (Idaho Code Title 54, Chapter 17). In 2025, House Bill 200 moved the Board's rules into statute and IDAPA 24.36.01, including its former compounding section 24.36.01.700, ceased to have effect on July 1, 2025. Compounding standards now sit in Idaho Code 54-1765 through 54-1767: section 54-1765 treats any compounding it does not permit as manufacturing, requires active ingredients from an FDA registered manufacturer with a certificate of analysis unless the ingredient meets a USP-NF monograph, prohibits compounding drugs FDA has identified as demonstrably difficult to compound or withdrawn from the market, limits copies of commercially available products, and requires policies that take into account USP chapters 795 and 797; section 54-1766 covers sterile preparation. Idaho's pharmacy law is shorter than most, but eligibility of a peptide for compounding still follows the federal 503A framework (approved drug component, USP or NF monograph, or FDA 503A bulks list). Under Idaho Code 54-1729, every drug outlet doing business in or into Idaho must be licensed or registered, a nonresident pharmacy must be licensed in good standing in its home state with a registered person in charge, and the Board may inspect a nonresident outlet at the outlet's expense if its home state will not. [1] [3] [4] [5] [6] [7]

Compounded GLP-1 access in Idaho

Branded Wegovy, Zepbound, Ozempic, and Mounjaro are available from Idaho pharmacies by prescription, and Idaho's virtual care law makes remote prescribing straightforward when the standard of care is met. Patients should confirm an out-of-state pharmacy is registered as a nonresident drug outlet with the Idaho Board. [2] [3] [10]

Research use only sellers in Idaho

Idaho Code 54-1729 requires every drug outlet doing business in or into Idaho to be licensed or registered with the Board of Pharmacy. "Research use only" peptides sold for human injection are unapproved new drugs under federal law regardless of labeling, are not dispensed by a pharmacist, and do not become lawful because Idaho's pharmacy rules are comparatively light. [3] [11]

Idaho notes on specific peptides

  • Semaglutide: Available branded by prescription, including through virtual care where the relationship is formed with virtual care technologies under Idaho Code 54-5705. Compounded semaglutide is limited to documented patient-specific needs since the 503A grace period ended April 22, 2025. [2] [10]

How to check a compounding pharmacy in Idaho

  1. Search the Idaho State Board of Pharmacy (Division of Occupational and Professional Licenses) license lookup for the pharmacy by name. A pharmacy based elsewhere needs whatever license or registration Idaho requires before it ships to you. [1] [3] [4] [5] [6] [7]
  2. Ask whether it operates as a 503A pharmacy or a 503B outsourcing facility, and confirm a 503B claim against FDA's outsourcing facility information (see the verification checklist).
  3. Confirm the peptide can be lawfully compounded: check its status on the regulatory tracker or its peptide page before paying.
  4. Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in Idaho. [3] [11]

Common questions in Idaho

What does an out-of-state pharmacy need to ship compounded peptides to Idaho?

Registration as a nonresident drug outlet with the Idaho State Board of Pharmacy under Idaho Code 54-1729, a home-state license in good standing, and a registered person in charge. Check the Division of Occupational and Professional Licenses lookup before ordering. [1] [3]

Does Idaho's lighter pharmacy rulebook mean more peptides can be compounded there?

No. Idaho's compounding statute, Idaho Code 54-1765, sets quality standards but does not create a state list of allowed substances, so eligibility still follows the federal 503A test, and peptides in FDA Category 2 cannot be compounded. [4] [7] [8]

Can an Idaho pharmacy compound BPC-157?

No, not from bulk today. BPC-157 is not on the 503A bulks list. PCAC's July 2026 recommendation is advisory, and until FDA publishes a final rule a 503A pharmacy has no federal basis to compound it from bulk. State boards cannot authorize what federal law does not. Peptides still in FDA Category 2 cannot be compounded either. [7] [8] [9]

All peptide legal questions for Idaho

Sources

  1. [1]Idaho State Board of Pharmacy, Division of Occupational and Professional Licenses
  2. [2]Idaho Code 54-5705, Provider-patient relationship (Idaho Virtual Care Access Act)
  3. [3]Idaho Code 54-1729, Registration and licensure of facilities (drug outlets, including nonresident)
  4. [4]Idaho Code 54-1765, Compounding drug preparations, general provisions (added 2025)
  5. [5]Idaho Code Title 54, Chapter 17, Pharmacists (including sections 54-1765 to 54-1767 on compounding)
  6. [6]Idaho Administrative Bulletin, July 2025: notice of revocation of IDAPA 24.36.01 (Docket 24-3601-2500) after House Bill 200
  7. [7]FDA: Section 503A of the Federal Food, Drug, and Cosmetic ActFDA
  8. [8]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (503A and 503B category lists)FDA
  9. [9]FDA: Pharmacy Compounding Advisory CommitteeFDA
  10. [10]FDA: concerns with unapproved GLP-1 drugs used for weight loss, including shortage resolution and compounding grace periodsFDA
  11. [11]21 U.S.C. 331, Prohibited acts